Approved indications
Janumet is FDA-approved as an add-on to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus; it is not for type 1 diabetes or for treating diabetic ketoacidosis.

Off-label uses
Clinicians may sometimes use the sitagliptin–metformin combination similarly to other DPP-4 inhibitor plus metformin regimens in people whose blood sugar is not well controlled on metformin alone, but there are no major established off-label indications beyond standard type 2 diabetes management.

Efficacy expectations
Many people see improved daily blood sugar readings within days to weeks, with A1C reductions typically evaluated after about 3 months. In clinical studies, adding sitagliptin to metformin usually lowers A1C by roughly 0.5–1 percentage point beyond metformin alone, depending on baseline levels. Compared with other add-on diabetes medicines, Janumet provides moderate A1C lowering, is weight-neutral (or may cause slight weight loss from the metformin component), and has a lower risk of hypoglycemia than insulin or sulfonylureas, but it generally provides less glucose lowering than newer GLP-1 receptor agonists or some SGLT2 inhibitors.

Typical dosing and how to take
Janumet is taken by mouth, usually one tablet twice daily with meals to reduce stomach upset, with available strengths combining 50 mg sitagliptin with 500 mg or 1000 mg metformin, or 100 mg sitagliptin with 1000 mg metformin (once- or twice-daily sitagliptin total dosing as prescribed). The exact strength is chosen based on the patient’s current metformin dose, kidney function, and blood sugar control goals. Tablets should be swallowed whole and not split, crushed, or chewed.

Special dosing instructions
Dose reductions or avoidance are needed in people with reduced kidney function, and the drug may need to be temporarily stopped before certain imaging procedures that use iodinated contrast dyes or during conditions causing dehydration, severe infection, or reduced oxygen supply to lower the risk of lactic acidosis. Your prescriber may start at a lower metformin dose and increase gradually to improve tolerability.

Missed dose guidance
If you miss a dose, take it as soon as you remember unless it is almost time for your next scheduled dose; if it is close to the next dose, skip the missed dose and resume your regular schedule. Do not take two doses at once to make up for a missed dose.

Overdose
Taking too much Janumet can increase the risk of severe gastrointestinal upset, very low blood sugar (especially if taken with other diabetes medicines that cause hypoglycemia), and lactic acidosis. In case of suspected overdose, seek emergency medical attention or contact a poison control center right away.

Common side effects
The most common side effects are from the metformin component and include nausea, diarrhea, stomach upset, gas, and decreased appetite, especially when starting or when the dose is increased; these are usually mild to moderate and often improve over days to weeks. Mild upper respiratory symptoms, headache, or nasopharyngitis can occur and are generally short-lived.

Serious or rare adverse effects
Serious but rare risks include lactic acidosis from the metformin component (a medical emergency, more likely in people with significant kidney, liver, or heart failure, severe infection, or heavy alcohol use) and pancreatitis from the sitagliptin component (symptoms can include severe, persistent abdominal pain that may radiate to the back, with or without vomiting). Other rare reactions include serious allergic or hypersensitivity reactions (such as swelling of the face, lips, tongue, or throat, severe rash, or trouble breathing), severe joint pain, or bullous skin reactions; any of these require immediate medical attention.

Warnings and precautions
Janumet is not recommended in people with severe kidney impairment or advanced kidney disease, and dose adjustments are needed with moderate kidney problems. It should be used cautiously in people with liver disease, heart failure, heavy alcohol use, or conditions that increase risk of dehydration or low oxygen states. During pregnancy, insulin is generally preferred for tight glucose control, and use of sitagliptin–metformin is typically based on individual risk–benefit discussion; metformin alone is sometimes used in pregnancy, but combination products are less well studied. Small amounts of metformin and possibly sitagliptin can pass into breast milk, so breastfeeding decisions should be individualized. It is not approved for use in children.

Relative safety compared with other drugs
Compared with many older agents like sulfonylureas, Janumet has a lower risk of hypoglycemia and is generally weight-neutral, but it carries specific risks such as lactic acidosis (metformin) and pancreatitis or severe joint pain (sitagliptin). Overall, when kidney and other contraindications are respected, it is considered a generally well-tolerated option for many adults with type 2 diabetes.

Reporting side effects and safety updates
Patients in the United States can report suspected side effects to the FDA’s MedWatch program (online or by phone) and should also inform their prescriber and pharmacist so that treatment can be reassessed and updated safety information can be discussed.

Drug and supplement interactions
Janumet can interact with medicines that affect kidney function or metformin levels, such as certain contrast dyes (iodinated contrast), some diuretics, and drugs that compete for kidney excretion (for example cationic drugs like cimetidine). Other diabetes medicines (insulin, sulfonylureas) can increase the risk of low blood sugar when used together and may require dose adjustments. Some heart and blood pressure drugs, steroids, and atypical antipsychotics can raise blood sugar and may lessen the glucose-lowering effect, requiring closer monitoring. No major direct interactions with most vitamins or common supplements are known, but it is best to review all products, including herbal supplements, with a healthcare professional.

Food, alcohol, and procedure-related interactions
Taking Janumet with food helps reduce stomach side effects from metformin. Excessive alcohol intake, especially binge drinking or chronic heavy use, increases the risk of lactic acidosis and should be avoided. Before imaging procedures that use iodinated contrast dye, Janumet may need to be withheld temporarily and restarted only after kidney function has been reassessed.

Precautions and conditions requiring caution
Use is not recommended in people with significant kidney impairment, unstable or acute heart failure, severe liver disease, or conditions associated with hypoxia (such as recent heart attack or severe respiratory disease), because these increase the risk of lactic acidosis. Patients with a history of pancreatitis should use sitagliptin-containing medicines cautiously, if at all. Elderly patients or those with multiple comorbidities require careful dosing and periodic review of kidney function.

Monitoring needs
Routine monitoring includes fasting blood glucose, A1C every 3–6 months, and periodic kidney function tests (serum creatinine and estimated GFR), especially in older adults or those with kidney disease. Liver tests may be checked if there is concern for liver problems. Patients should be monitored clinically for symptoms of pancreatitis (severe abdominal pain), lactic acidosis (unexplained fatigue, muscle pain, trouble breathing, abdominal discomfort), and allergic reactions.

Q: Is Janumet the same as metformin, and why would I take it instead of metformin alone?
A: Janumet combines metformin with sitagliptin, which works in a different way to help your body release more insulin and reduce sugar made by the liver after meals, so it may lower A1C more than metformin alone in people whose blood sugar is still high on metformin and lifestyle changes.

Q: How long does it take for Janumet to start working on my blood sugar?
A: Metformin and sitagliptin start lowering blood sugar within days, but you will typically see the full effect on your A1C (average blood sugar) over about 2–3 months of regular use.

Q: Can Janumet cause low blood sugar (hypoglycemia)?
A: When used alone or just with metformin, Janumet has a relatively low risk of causing low blood sugar, but the risk increases if it is combined with other medicines such as insulin or sulfonylureas, if you skip meals, or if you drink alcohol heavily.

Q: Do I need to stop Janumet before surgery or contrast dye tests?
A: Your healthcare team may tell you to stop Janumet temporarily before major surgery or certain imaging procedures with iodinated contrast and restart it only after your kidney function and overall condition have been checked.

Q: If I feel better and my sugars improve, can I stop taking Janumet?
A: Improved blood sugar is usually a sign that the medicine and lifestyle changes are working, so you should not stop Janumet without talking to your prescriber, who can decide whether dose adjustments, switching medicines, or continued treatment is best for your long-term diabetes control.

Storage
Store Janumet tablets at room temperature (generally 68°F to 77°F / 20°C to 25°C), away from excess heat, moisture, and light, and keep the bottle tightly closed and out of reach of children and pets.

Disposal
Do not flush Janumet down the toilet or pour it into drains; use a local medication take-back program if available, or follow pharmacy or community guidelines for safe disposal in household trash (such as mixing tablets with undesirable material in a sealed container before discarding).